Triple Hair Group Receives EMA Approval to Start Phase III Clinical Trials on its Therapy-07 Prescription Drug in Europe
19 Junio 2024 - 6:30AM
Triple Hair Group Inc. (“
Triple Hair” or the
“
Company”), a company specializing in the
development of innovative treatments for androgenic alopecia, is
pleased to announce that it has received approval from the European
Medicines Agency (EMA), allowing it to move forward with Phase III
clinical trials of its flagship prescription product Therapy-07 in
Europe. The clinical trial will commence upon notification to the
Agency of the completion status of certain cGMP requirements.
“Receiving the EMA approval to start our Phase
III trial is a major milestone for Triple Hair and a testament to
the quality of the regulatory plan we submitted,” said
Jean-Philippe Gravel, President and CEO of Triple Hair. “While we
await other regulatory approvals, this latest approval will allow
us to further strengthen our capital structure so that we can begin
clinical trials in multiple countries.”
The Phase III trials are designed to measure the
efficacy of Therapy-07 on hair regrowth in the treatment of
androgenic alopecia.
According to a report published by Grand View
Research, Inc. alopecia is an underserved global market valued at
US$8.8 billion in 2023, and expected to reach US$16 billion by
2030.
About Triple HairTriple Hair
Group Inc. is a Canadian biotechnology company specializing in the
development of innovative treatments for men and women suffering
from androgenic alopecia. Its mission is to provide the underserved
market with clinically proven and effective prescription hair
regrowth treatments. The Company also sells patented
over-the-counter natural hair growth products under the RIZNTM and
Plenty NaturalTM brands.
For more information, visit the Company’s website, at
www.triplehair.ca/investors.
Contact:Triple Hair
GroupJean-Philippe GravelPresident and
CEOinvestors@triplehair.ca
This press release may contain forward-looking
statements, which are subject to certain factors, including risks
and uncertainties that could cause actual results to differ
materially from what the Company currently expects. Therefore,
future events and results may vary significantly from what
management currently foresees. The reader should not place undue
importance on forward-looking information and should not rely upon
this information as of any other date.